Some health conditions or clinical circumstances may prevent safe or appropriate use of weight loss injectable treatments such as Mounjaro® and Wegovy®.
Overview
This article explains:
Medical conditions that may exclude treatment
Situations where prescribing requires extra caution
How prescribers decide clinical suitability
Use this information to understand condition-based eligibility for GLP-1 treatment.
Conditions that may prevent prescribing
Weight loss injectables may not be appropriate in people with:
History of pancreatitis or pancreatic disease
Severe liver or kidney disease
Unstable mental health conditions affecting safe treatment use
Eating disorders or medically unsafe weight-loss behaviour
Any illness where rapid weight change may be harmful
These factors can increase treatment risk.
Situations requiring careful clinical review
Some conditions do not always prevent treatment but may require:
Closer clinical monitoring
Dose adjustment or slower escalation
Consideration of alternative treatments
Prescribers assess:
Overall health status
Medication interactions
Ability to follow treatment safely
Why condition-specific exclusions exist
Condition-based restrictions ensure:
Safe prescribing aligned with medical guidance
Reduced risk of complications
Appropriate use of GLP-1 weight-management therapy
Safety remains the primary clinical priority.
Key takeaway
Certain medical conditions may exclude or limit treatment with Mounjaro® or Wegovy®.
Some cases require enhanced monitoring rather than full exclusion.
Final eligibility depends on individual clinical assessment.
If you still need help after reviewing the information above, additional assistance is available.